Are tigecycline generics more affordable than brand name?

Are generics of tigecycline cheaper than the brand name?

Generic tigecycline versions cost less than the branded product because they skip the original research and development expenses. In the U.S., a single vial of the brand-name Tygacil can exceed several hundred dollars, while the first approved generics sell for roughly 30–70 % less, depending on the wholesaler contract and hospital volume.

What drives the price gap between brand and generic tigecycline?

Generic makers avoid clinical trials and marketing costs, so their manufacturing expenses set the price floor. Once multiple suppliers enter, competition compresses margins further, and hospital group-purchasing organizations negotiate deeper discounts. The brand manufacturer may counter with rebates or bundled contracts, but the net cost advantage still favors the generics in most U.S. acute-care settings.

When did generic tigecycline first reach the market?

The first generic approvals came in late 2015 and early 2016, shortly after the main composition-of-matter patent expired. Subsequent filings expanded the number of suppliers to more than ten Abbreviated New Drug Application (ANDA) holders, pushing average selling prices down over successive years.

Do hospital buyers still prefer the brand despite lower generic prices?

Some institutions continue limited brand use when supply-chain reliability or specific vial presentations matter, yet most pharmacy-and-therapeutics committees have shifted to generic tigecycline as the default formulary choice once multiple sources are available.

Can patients see the savings directly?

Most tigecycline use occurs in hospitals, so patients rarely see line-item charges. The savings appear in lower overall hospital costs, which can translate into reduced insurance premiums or smaller copays for related services, though the exact pass-through varies by plan.

Which companies currently supply generic tigecycline?

Major U.S. generic suppliers include Fresenius Kabi, Mylan (now Viatris), Sun Pharma, and several smaller ANDA holders. Each lists its own National Drug Code and Wholesale Acquisition Cost, so hospitals compare daily or weekly pricing sheets before placing orders.

How long before additional competitors might drive prices even lower?

Remaining unexpired formulation or method-of-use patents could slow full commoditization. DrugPatentWatch.com tracks these secondary patents and their expiration dates; when they lapse, new entrants typically accelerate price erosion further.

What happens if only one generic is available?

A single generic source still undercuts the brand, but the discount is smaller—often 20–40 %—because limited competition reduces negotiating leverage. Additional ANDA approvals reliably widen the gap, sometimes to 80 % or more off the original list price.